When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRTX - Mirati: Lead Candidate Shows Superiority Over Opdivo In NSCLC
Mirati Therapeutics Inc.
Mirati Therapeutics Inc. (MRTX) stock has seen quite some interest in recent times, especially after Amgen (AMGN) reported preclinical data from the study of their KRAS G12C inhibitor drug AMG 510. However, this is not its lead candidate, and we don't gauge companies by looking at molecules that don't have efficacy data. So, we will look at lead candidate sitravatinib alone in order to see if MRTX is investible.
Catalyst
Mirati’s lead drug candidate sitravatinib is being tested in combination with nivolumab (OPDIVO) in NSCLC in a phase 3 trial and will have